Sir,

With interest we read the article by Kulkarni *et al*.,\[[@ref1]\] and appreciate their efforts to validate rocuronium 0.9 mg as better alternative to succinylcholine for moderate duration surgeries in pediatric patients. We would like to share with the readers our center\'s experience in pediatric patients with congenital heart diseases (cyanotic and acyanotic) undergoing cardiac surgeries.

Rocuronium can be considered a suitable alternative to succinylcholine for rapid-sequence induction in most clinical situations except in clinical situations demanding absolute optimization of intubating conditions or when the longer duration of action of rocuronium is contraindicated. Magorian *et al*.\[[@ref2]\] compared three different doses (0.6, 0.9 and 1.2 mg/ kg) of rocuronium with 1 mg/kg succinylcholine and found that the onset times of rocuronium in doses of 0.9 and 1.2 mg/kg were similar to that of succinylcholine. They concluded that rocuronium 0.6-1.2 mg/kg is the appropriate dose for rapid sequence induction. The only disadvantage of high dose (1.2 mg/kg) was the longer duration of action, which was not desirable in short procedures. Considerable debate continues over the dosing of rocuronium in rapid sequence intubation in comparison to succinylcholine, with some studies stating the dose of rocuronium needed to be at least 1.0 mg/kg or even as high as 2.0 mg/kg.\[[@ref2][@ref3]\]

Surgeries at out center have a minimum duration of 1--1½ h and thus duration of neuromuscular blockade is not an issue. We follow the intubation doses used by Sparr *et al*. i.e. 1.5 mg rocuronium. In contrast to most debated studies which used propofol, we use sevoflurane 3--5% in a 50 : 50 air : oxygen mixture for inhalational induction of anesthesia. An intravenous access line is secured, fentanyl 3 mcg/kg and rocuronium 1.5 mg/kg intravenous are administered and sevoflurane is tapered off. Excellent intubating conditions are achieved at 30 s, with no episodes of hemodynamic or respiratory sequelae in a high risk patient population, while keeping at bay the unwanted effects of succinylcholine. These conditions can be attributed to both the initial use of sevoflurane and the quick onset of rocuronium. Further studies are required to determine whether rocuronium can be exclusively credited for these effects, as this condition is also not achieved with the sole use of sevoflurane either.
